Document Details
|
Document Type |
: |
Article In Journal |
|
Document Title |
: |
Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques |
|
Document Language |
: |
English |
|
Abstract |
: |
Background: Her2/neu is an oncogene that plays an important role in the pathogenesis of many cancer types. In
bladder carcinoma (BC), the clinical significance of Her2/neu status remains under-investigated and poorly linked to
the patients’ clinic-pathological features and survival status. Thus, the current study was conducted to assess Her2/
neu status in a cohort of patients’ in Saudi Arabia, and to explore its prognostic value in BC.
Methods: A total of 160 consent patients of transitional cell carcinoma (TCC) of bladder were arranged on a tissue
microarray (TMA) and stained by immunohistochemistry (IHC) and bright-field dual in situ hybridization (BDISH)
methods. The intensity of Her2/neu protein receptor immunostaining was evaluated, correlated to Her2/neu gene
amplification status in TCC and assessed for potential clinical value by correlation measures.
Results: IHC data demonstrated that Her2/neu protein is expressed in 60 % (2+ and 3+) of our TCC patient’s cohort
from Saudi Arabia. Her2/neu gene amplification is detected in 25 % by BDISH. There was a strong association
between Her2/neu protein levels and lymph node invasion (p = 0.04), tumor stage (p = 0.002), vascular invasion and
borderline significance with distant metastasis (p = 0.07). Amplification of Her2/neu gene was associated with tumor
grade (p = 0.03) and poor disease-specific survival (p = 0.02), in that, patients with non-amplified Her2/neu gene live
longer. Interestingly, there was a reasonable concordance rate (71 %) between IHC and BDISH data in the analyzed
cohort.
Conclusion: The study showed that 25 % of our patients’ cohort has Her2/neu over-expression. This Her2/neu
(over-expression/amplification) status was concordant using either IHC or BDISH and significantly associated with
disease aggressiveness and poor outcome. These findings suggested a potential impact of anti-Her2 targeted
therapy in the treatment of bladder cancer with amplified/overexpressed HER2 that needs further investigation. |
|
ISSN |
: |
1471-2407 |
|
Journal Name |
: |
BMC cancer |
|
Volume |
: |
16 |
|
Issue Number |
: |
1 |
|
Publishing Year |
: |
1437 AH
2016 AD |
|
Article Type |
: |
Article |
|
Added Date |
: |
Tuesday, July 18, 2017 |
|
Researchers
| Taoufik Nedjadi | Nedjadi, Taoufik | Researcher | Doctorate | |
| Jaudah Al-Maghrabi | Al-Maghrabi, Jaudah | Researcher | Doctorate | |
| Mourad Assidi | Assidi, Mourad | Researcher | Doctorate | |
| Ashraf Dallol | Dallol, Ashraf | Researcher | Doctorate | |
| Heba Al-Kattabi | Al-Kattabi, Heba | Researcher | Doctorate | |
| Adeel Chaudhary | Chaudhary, Adeel | Researcher | Doctorate | |
| Ahmed Al-Sayyad | Al-Sayyad, Ahmed | Researcher | Doctorate | |
| Adel Al-Ammari | Al-Ammari, Adel | Researcher | Doctorate | |
| Adel Abuzenadah | Abuzenadah, Adel | Researcher | Doctorate | |
| Abdelbaset Buhmeida | Buhmeida, Abdelbaset | Researcher | Doctorate | |
| Mohammed Al-Qahtani | Al-Qahtani, Mohammed | Researcher | Doctorate | |
|
Back To Researches Page
|